Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-04-08
1999-08-17
Berch, Mark L
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514266, 544276, 544277, A61K 3152, C07D47334, C07D47324
Patent
active
059394226
DESCRIPTION:
BRIEF SUMMARY
This application is a national stage application of International application PCT/GB94/01334, filed Jun. 21, 1994, under 35 U.S.C. .sctn. 371.
BACKGROUND OF THE INVENTION
The present invention relates to purine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their medical use. In particular the invention relates to 3-substituted and 3,8-disubstituted 6-amino purine derivatives having bronchial and tracheal relaxation and/or anti-inflammatory activity. The invention is also related to the thioisoguanine and dithioxanthine precursor compounds of these purine derivatives, to pharmaceutical compositions containing them and to their medical use.
Cyclic nucleotide phosphodiesterases (PDEs) have received considerable attention as molecular targets for anti-asthmatic agents. Cyclic 3',5'-adenosine monophosphate (cAMP) and cyclic 3',5'-guanosine monophosphate (cGMP) are known second messengers that mediate the functional responses of cells to a multitude of hormones, neurotransmitters and autocoids. At least two therapeutically important effects could result from phosphodiesterase inhibition, and the consequent rise in intracellular cyclic adenosine 3',5'-cyclicmonophosphate (cAMP) or guanosine 3',5'-cyclicmonophosphate (cGMP) in key cells in the pathophysiology of asthma. These are smooth muscle relaxation (resulting in bronchodilation) and anti-inflammatory activity.
It has become known that there are multiple, distinct PDE isoenzymes which differ in their cellular distribution. A variety of inhibitors possessing a marked degree of selectivity for one isoenzyme or the other have been synthesized.
The structure-activity relationships (SAR) of isozyme-selective inhibitors has been discussed in detail, e.g., in the article of Theodore J. Torphy, et al., "Novel Phosphodiesterases Inhibitors For The Therapy Of Asthma", Drug News & Prospectives, 6(4) May 1993, pages 203-214. The PDE enzymes can be grouped into five or more families according to their specificity toward hydrolysis of cAMP or cGMP, their sensitivity to regulation by calcium, calmodulin or cGMP, and their selective inhibition by various compounds. PDE I is stimulated by Ca.sup.2+ /calmodulin. PDE II is cGMP-stimulated, and is found in the heart and adrenals. PDE III is cGMP-inhibited, and possesses positive inotropic activity. PDE IV is cAMP specific, and possesses airway relaxation, antiinflammatory and antidepressant activity. PDE V appears to be important in regulating cGMP content in vascular smooth muscle, and therefore PDE V inhibitors may have cardiovascular activity.
While there are compounds derived from numerous structure activity relationship studies which provide PDE III inhibition, the number of structural classes of PDE IV inhibitors is relatively limited.
It has previously been shown that the 3,8-disubstituted 6-thioxanthine derivatives as described in EP-A-0256692 exhibit enhanced bronchodilator and anti-inflammatory activity compared to the corresponding xanthine derivatives. Transformation of these 6-thioxanthine derivatives to the corresponding thioisoguanines substantially reduces the bronchodilator and anti-inflammatory activity in certain tests.
PDE IV (and possibly PDE V) is present in all the major inflammatory cells in asthma including eosinophils, neutrophils, T-lymphocytes, macrophages and endothelial cells. Its inhibition causes down regulation of cellular activation and relaxes smooth muscle cells in the trachea and bronchus. On the other hand, inhibition of PDE III, which is present in myocardium, causes an increase in both the force and rate of cardiac contractility. These are undesirable side effects for an anti-inflammatory agent. Theophylline, a non-selective PDE inhibitor, inhibits both PDE III and PDE IV, resulting in both desirable anti-asthmatic effects and undesirable cardiovascular stimulation. With this well-known distinction between PDE isozymes, the opportunity for concomitant anti-inflammation and bronchodilation without many of the side effects associate
REFERENCES:
patent: Re31429 (1983-10-01), Tull et al.
patent: 2320654 (1943-06-01), Riester
patent: 2691654 (1954-10-01), Hitchings
patent: 2844577 (1958-07-01), Acker
patent: 2903455 (1959-09-01), Strong
patent: 2956998 (1960-10-01), Baizer
patent: 2957875 (1960-10-01), Lyttle
patent: 2966488 (1960-12-01), Shive
patent: 3079378 (1963-02-01), Schroeder
patent: 3129225 (1964-04-01), Shapiro
patent: 3135753 (1964-06-01), Hitchings
patent: 3136771 (1964-06-01), Liechti et al.
patent: 3215696 (1965-11-01), Denayer
patent: 3225046 (1965-12-01), Zwahlen
patent: 3262929 (1966-07-01), Okubu et al.
patent: 3470164 (1969-09-01), Takamatsu
patent: 3491091 (1970-01-01), Berger
patent: 3491106 (1970-01-01), Freyermuth
patent: 3494919 (1970-02-01), Collins et al.
patent: 3516997 (1970-06-01), Takano et al.
patent: 3541100 (1970-11-01), Ramirez et al.
patent: 3551554 (1970-12-01), Herschler
patent: 3574218 (1971-04-01), Hideg et al.
patent: 3586670 (1971-06-01), Brenneisen
patent: 3590029 (1971-06-01), Koch
patent: 3626018 (1971-12-01), Taylor
patent: 3636039 (1972-01-01), Gruenman et al.
patent: 3647812 (1972-03-01), Smith
patent: 3658799 (1972-04-01), Eardley
patent: 3666769 (1972-05-01), Jones
patent: 3669979 (1972-06-01), Freyermuth
patent: 3674781 (1972-07-01), Schinzel et al.
patent: 3681328 (1972-08-01), Kurita
patent: 3686238 (1972-08-01), Zaffaroni
patent: 3706834 (1972-12-01), Scheilenbaum et al.
patent: 3923833 (1975-12-01), Gruenman et al.
patent: 3962452 (1976-06-01), Evans et al.
patent: 4020165 (1977-04-01), Hubbard
patent: 4025636 (1977-05-01), Dunwell et al.
patent: 4025637 (1977-05-01), Dunwell et al.
patent: 4107306 (1978-08-01), Voorhees
patent: 4146721 (1979-03-01), Rainer
patent: 4167628 (1979-09-01), Kormany
patent: 4233303 (1980-11-01), Bergstrand et al.
patent: 4241063 (1980-12-01), Naito et al.
patent: 4241168 (1980-12-01), Arai
patent: 4308278 (1981-12-01), Schneider et al.
patent: 4361699 (1982-11-01), Rasmusson et al.
patent: 4407802 (1983-10-01), Graham et al.
patent: 4416892 (1983-11-01), Dawson
patent: 4454138 (1984-06-01), Goring
patent: 4469698 (1984-09-01), Philippossian et al.
patent: 4495195 (1985-01-01), Beck et al.
patent: 4616020 (1986-10-01), Furrer et al.
patent: 4652654 (1987-03-01), Verga et al.
patent: 4684656 (1987-08-01), Atwal
patent: 4684728 (1987-08-01), Mohring
patent: 4710503 (1987-12-01), Hofer
patent: 4732978 (1988-03-01), Kreft et al.
patent: 4755517 (1988-07-01), Bruns et al.
patent: 4757124 (1988-07-01), Koyanagi
patent: 4769377 (1988-09-01), Snyder et al.
patent: 4770990 (1988-09-01), Nakamura
patent: 4803216 (1989-02-01), Appleton et al.
patent: 4810719 (1989-03-01), Appleton et al.
patent: 4826868 (1989-05-01), Wachter et al.
patent: 4831152 (1989-05-01), Itoh et al.
patent: 4851321 (1989-07-01), Takagi
patent: 4868183 (1989-09-01), Kanai et al.
patent: 4874869 (1989-10-01), Ueda et al.
patent: 4883801 (1989-11-01), Nathanson
patent: 4910211 (1990-03-01), Imamura et al.
patent: 4918074 (1990-04-01), Tsuda et al.
patent: 4925847 (1990-05-01), Hofer
patent: 4965169 (1990-10-01), Hirano
patent: 4971972 (1990-11-01), Doll et al.
patent: 4981857 (1991-01-01), Daluge
patent: 4994363 (1991-02-01), Koya et al.
patent: 5010081 (1991-04-01), Hofer
patent: 5047411 (1991-09-01), Takasugi et al.
patent: 5057517 (1991-10-01), Johnston et al.
patent: 5068236 (1991-11-01), Suzuki et al.
patent: 5091431 (1992-02-01), Tulshian et al.
patent: 5098464 (1992-03-01), Barton et al.
patent: 5110818 (1992-05-01), Allgeier
patent: 5114835 (1992-05-01), Sakanoue
patent: 5116717 (1992-05-01), Matsushita
patent: 5117830 (1992-06-01), McAfee
patent: 5139921 (1992-08-01), Takagi et al.
patent: 5177074 (1993-01-01), Allen et al.
patent: 5190942 (1993-03-01), Poss
patent: 5191084 (1993-03-01), Bagli et al.
patent: 5206255 (1993-04-01), Ubasawa et al.
patent: 5264589 (1993-11-01), Corey
patent: 5270206 (1993-12-01), Saccomano
patent: 5288896 (1994-02-01), Capiris et al.
patent: 5290782 (1994-03-01), Suzuki et al.
patent: 5322847 (1994-06-01), Ma
Cavalla David
Chasin Mark
Gehrig Anddre
Hofer Peter
Wintergest Peter
Berch Mark L
Euro-Celtique S.A.
LandOfFree
Chemical compounds having PDE-IV inhibition activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemical compounds having PDE-IV inhibition activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemical compounds having PDE-IV inhibition activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-314998